Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

NoAb Working With SAGE Labs

By Drug Discovery Trends Editor | July 11, 2012

NoAb BioDiscoveries, in collaboration with Sigma Advanced Genetic Engineering (SAGE) Labs, is introducing the use of SAGE knockout rats with its tools to investigate the blood-brain barrier including microdialysis and serial CSF collection, as a service to drug discovery researchers. Rats provided by SAGE Labs are available with knockouts of the specific drug transporter genes Mdr1a, Mrp1, Mrp2, Bcrp, or Oct1. These advanced animal models are designed to study and characterize the drug-like properties of compounds in vivo.

Dan Lichtman, President and CEO of NoAb BioDiscoveries, said “This partnership with SAGE Labs strengthens our service offering in drug discovery research. Preclinical researchers will benefit from the combined expertise and leadership of NoAb and SAGE.”

NoAb BioDiscoveries is a preclinical Contract Research Organization that offers a wide range ADME-PK Discovery services, specializing in in vivo models, in vitro assays and bioanalytical support. In addition to standard drug disposition studies, specific surgical catheterization points available at NoAb BioDiscoveries include jugular vein, carotid artery, hepatoportal vein, bile duct, and intestinal subsections. Such customized models form an important component of the tools that an investigator can use to address unique and specific questions about their compounds.

Date: July 1, 2012
Source: NoAb BioDiscoveries

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50